Phase I study of bryostatin 1 and gemcitabine

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7059-7062

  El Rayes, Basil F ^a   Gadgeel, Shirish ^a   Shields, Anthony F ^a   Manza, Stephanie ^a   Lorusso, Patricia ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; GEMCITABINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE ESCALATION; FEMALE; HUMAN; LIFE EXPECTANCY; MALE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 33845777994     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1419     Document Type: Article

References (26)

1. Deacon EM, Pongracz J, Griffiths G, Lord JM. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 1997;50: 124-31.
2. Philip PA, Harris AL. Potential for protein kinase C inhibitors in cancer therapy. Cancer Treat Res 1995; 78:3-27.
3. Azzi A, Boscoboinik D, Hensey C. The protein kinase C family. Eur J Biochem 1992;208:547-57.
4. Gordge PC, Hulme MJ, Clegg RA, Miller WR. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 1996;32A:2120-6.
5. O'Brian C, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989;49:3215-7.
6. El-Rayes BF, Ali S, Sarkar F, Philip PA. Protein kinase C: a target for therapy in pancreatic cancer. ASCO proceedings, 2003.
7. Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic targeting in antineoplastic treatment strategies. Invest New Drugs 1999;17:227-40.
8. Pettit GR, Gao F, Blumberg PM, et al. Antineoplastic agents. 340. Isolation and structural eludication of bryostatins 16-18. J Nat Prod 1996;59:286-9.
9. Kortmansky J, Schwartz GK. Bryostatin 1: a novel PKC inhibitor in clinical development. Cancer Invest 2003;21:924-36.
10. Jayson GC, Crowther D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995;72:461-8.
11. Philip PA, Rea D, Thavsau P, et al. A phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993;85:1812-8.
12. Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin I in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001;7:38-42.
13. Pagliaro L, Daliani D, Amato R, et al. A phase II trial of bryostatin 1 for patients with metastatic renal call carcinoma. Cancer 2000;89:615-8.
14. Propper DJ, Macaulay C, O'Byrne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998;78:1337-41.
15. Brockstein B, Samuels B, Humerickhouse R, et al. Phase II studies of bryostatin 1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 2001;19:249-54.
16. Ali S, Aranha O, Li Y, Pettit GR, Sarkar FH, Philip PA. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother Pharmacol 2003;52: 235-46.
17. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9: 491-8.
18. Martin C, Pollera CF. Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res 1996;16:9-18.
19. Burris HA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer; a randomized trial. J Clin Oncol 1997; 15:2403-13.
20. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2431-6.
21. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappusso F. Role of gemcitabine in cancer therapy. Future Oncol 2005;1:7-17.
22. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine. Non-Small Cell Lung Cancer Br J Cancer 2000;83:447-53.
23. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R, Yuspa SH. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 1987; 8:1343-6.
24. Cragg LH, Andreeff M, Feldman E, et al. Phase I trial and correlative larobatory studies of bryostatin 1 (NSC 339555) and high-dose 1-β-D-arabionfuranosycytosine in patients with refractory acute leukemia. Clin Cancer Res 2002;8:2123-33.
25. Dowlati A, Lazarus HM, Hartman P, et al. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res 2003;9:5929-35.
26. Heinemann V, Hertel LW, Grindley GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48: 4024-31.